Symon Erskine

Symon Erskine is the Vice President of Science & Early Commercialisation at Renavatio, a position held since August 2009. Prior experience includes a tenure at GlaxoSmithKline from February 1999 to July 2009, where Symon served as Investigator & Program Leader in Oncology, contributing to the development of GSK1120212 (Mekinist) and GSK 2118436 (Tafinlar), among other clinical candidates. Earlier roles at GlaxoSmithKline included Investigator & Project Leader in Anti-infectives and Senior Scientist in New Assay Technologies, focusing on early phase programs and mechanistic enzymology. Symon's academic foundation includes a PhD in Enzyme Kinetics and DNA-Protein interactions from the University of Bristol and an MSc in Biochemistry and Biophysics from Newcastle University, complemented by postdoctoral research at the University of Leicester.